CUE vs LYEL
CUE: Cue Biopharma engineers injectable biologics that selectively modulate disease-specific T cells to restore immune tolerance in autoimmune diseases and activate anti-tumor immunity in cancer. LYEL: Late-stage clinical cell therapy company engineering next-generation dual-targeting CD19/CD20 CAR T-cell therapies for blood cancers and solid tumors, with a lead program in pivotal trials and an in-house manufacturing facility.
Side-by-side fundamentals
| Metric | CUE | LYEL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $34.20 | $12.84 | |
| Market cap as of 2026-07-23 | $144M | $315M | |
| Net margin as of 2026-07-23 | -59.6% | -794858.1% | CUE higher |
| Operating margin as of 2026-07-23 | -59.9% | -823341.9% | CUE higher |
| ROE as of 2026-07-23 | -98.3% | -85.7% | LYEL higher |
| ROA as of 2026-07-23 | -53.7% | -66.4% | CUE higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +309.6% | -52.3% | CUE higher |
| Revenue CAGR (3y) SEC XBRL | +180.5% | -92.5% | CUE higher |
| Beta as of 2026-07-23 | 2.49 | -0.05 | |
| 1-year return as of 2026-07-22 close | +26.3% | +38.1% | LYEL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.